Telomir Pharmaceuticals, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Telomir Pharmaceuticals, Inc. (market cap ~$18.1M) filed its Q2 2026 10-Q on 2026-08-13 for the period ending 2026-06-30. The filing document itself contains no disclosed financial metrics, deal announcements, counterparties, dollar amounts, or material operational changes in the metadata provided — only standard SEC submission structure and XBRL data files. Substantive financial and operational details are not accessible from this filing index page.
Why this rating
Routine quarterly reporting compliance filing with no material events disclosed in available metadata. Company size immaterial to assessment.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.